

FILED ELECTRONICALLY

Docket No. TPI5013USPCT2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Steven Bernstein et al.

Serial No.: 10/534,612

Group No.: 1618

Filed: 11/18/2005

Examiner: Zohreh Fay

For: PHARMACEUTICAL FORMULATIONS OF CELECOXIB

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Please disregard the previous transmittal of the Supplemental Information Disclosure Statement that was filed via EFS on January 29, 2007, as it listed the incorrect patent application details as now correctly referenced above. Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Supplemental Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth

in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2).

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/TPI5013USPCT2/PB. This form is submitted in triplicate.

Respectfully submitted,

Dated: January 29, 2007
TransForm Pharmaceuticals, Inc.
c/o Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
Telephone: (781) 674-7816
Facsimile: (732) 524-2808

/Paul Burgess/
Paul Burgess, Attorney for Applicants
Reg. No. 53,852
Customer No. 27777